Drug intelligence / Profile preview

JW0105

Development stage: Unknown
Lead developer: JW Pharmaceutical
Administration: Oral

Overview

JW0105 is an investigational drug under clinical evaluation by JW Pharmaceutical. It is being studied to assess its safety and pharmacokinetic characteristics when administered alone in healthy volunteers, as well as in comparison to or co-administration with other compounds (JW0104 and C2402). The precise mechanism of action, chemical class, and intended therapeutic indication of JW0105 have not been disclosed in the referenced clinical studies. The studies focus on pharmacokinetics and safety in healthy volunteers under fasting conditions[1][5][7].

Beyond the preview

Go deeper on JW0105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0105.

Explore the full profile